Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Researchers develop new inexpensive way of filtering water with silver nanoparticles

Disasters such as floods, tsunamis, and earthquakes often result in the spread of diseases like gastroenteritis, giardiasis and even cholera because of an immediate shortage of clean drinking water. Now, chemistry researchers at McGill University have taken a key step towards making a cheap, portable, paper-based filter coated with silver nanoparticles to be used in these emergency settings.

24 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

FDA allows marketing of Ridascreen Norovirus 3rd Generation EIA assay in the US

The U.S. Food and Drug Administration allowed marketing of the first test for the preliminary identification of norovirus.

24 Feb 2011

BRI and Eureka Genomics form strategic alliance to advance cancer treatments

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and bioinformatics pioneer Eureka Genomics (EG) have formed a strategic alliance to achieve a better understanding of the causes of colorectal cancer, potentially leading to advancements in the disease's prevention, management and treatment.

24 Feb 2011

Scientists find bovine colostrum can massively reduce leaky gut syndrome

Scientists investigating natural ways to enhance athletic performance have found that bovine colostrum can massively reduce gut permeability - otherwise known as 'leaky gut syndrome.'

24 Feb 2011

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

ASGE announces 35 new honorees under Endoscopy Unit Recognition Program

The American Society for Gastrointestinal Endoscopy (ASGE) has recognized 35 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States. The ASGE Endoscopy Unit Recognition Program honors endoscopy units that follow the ASGE guidelines on privileging, quality assurance, endoscopy reprocessing and CDC infection control guidelines. To date, 307 endoscopy units have been recognized by ASGE.

23 Feb 2011

Nationwide Children's Hospital joins Autism Speaks ATN to offer patient care

Nationwide Children's Hospital has been selected to join the Autism Speaks Autism Treatment Network, connecting Columbus with Cincinnati Children's Hospital Medical Center and the University of Missouri as the nation's only ATN institutions in the Midwest region.

23 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

New research demonstrates how climate change can increase exposure, risk of human illness

A panel of scientists speaking today at the annual meeting of the American Association for the Advancement of Science unveiled new research and models demonstrating how climate change could increase exposure and risk of human illness originating from ocean, coastal and Great Lakes ecosystems, with some studies projecting impacts to be felt within 30 years.

20 Feb 2011

Kentucky, Virginia LapBand centers install Crospon's EndoFLIP system

Crospon, an Irish medical device developer based in Galway, has announced that its EndoFLIP system is now being used in two leading LapBand centers in Kentucky and Virginia.

19 Feb 2011

EGS publishes three clinical studies on TIF procedure over past four months

EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced that three clinical studies on transoral fundoplication have been published over the past four months.

18 Feb 2011

New study: Asthma may have relationship with airway microbiota composition

Asthma may have a surprising relationship with the composition of the species of bacteria that inhabit bronchial airways, a finding that could suggest new treatment or even potential cures for the common inflammatory disease, according to a new UCSF-led study.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

New method may eliminate colonoscopies

Nobody enjoys colonoscopies, including mice. University of Missouri researchers are excited about the potential of using genetic biomarkers to predict colon cancer caused by inflammation. A new method developed at the MU Research Animal Diagnostic Laboratory (RADIL) could eventually lead to a method that might eliminate colonoscopies altogether.

17 Feb 2011

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, gave a presentation about its E. coli O157 cattle vaccine at the First International One Health Congress in Melbourne, Victoria, Australia.

16 Feb 2011

Study: BPS is safe and effective for patients undergoing therapeutic endoscopy

Researchers from Korea report that, compared with conventional sedation, balanced propofol sedation using propofol in combination with midazolam and meperidine, provided higher health care provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.

16 Feb 2011